AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2017

Feb 23, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AGIOS PHARMACEUTICALS INC (AGIO)
CIK: 0001439222
Period of Report: 2017-02-21

Reporting Person: Bowden Christopher (Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-02-21	Stock option (right to buy)	$50.40	A	47600	Acquired	2027-02-20	Common stock (47600)	Direct

Footnotes

F1: This option was granted on February 21, 2017. The shares underlying this option vest as to 25% of the underlying shares on February 21, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter.